ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1028

Assessment of Patient-Reported Outcomes in Juvenile Idiopathic Arthritis by Race, Ethnicity, and Insurance Type in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry

Julia Harris1, Nancy Pan2, Catherine Bingham3, Sheetal Vora4, Cagri Yildirim-Toruner5, Kerry Ferraro6, Erik Friedrichsen7, Michelle Batthish8, Jon Burnham9, Danielle Fair10, Suhas Ganguli11, Mileka Gilbert12, Beth Gottlieb13, Olha Halyabar14, Melissa Hazen15, Tzielan Lee16, Daniel Lovell17, Melissa Mannion18, Edward Oberle19, Linda Ray20, Michael Shishov21, Mary Toth22 and Esi Morgan23, 1Children's Mercy Kansas City, Overland Park, KS, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 3Penn State Children’s Hospital, Hershey, 4Atrium Health Levine Children's Hospital, Charlotte, NC, 5Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, 6JIA parent and CHOP volunteer, Lower Gwynedd, PA, 7Seattle Children's Hospital, Seattle, 8McMaster Children's Hospital, Hamilton, ON, Canada, 9Children's Hospital of Philadelphia, Philadelphia, PA, 10Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, 11Hackensack University Medical Center, Hackensack, 12Medical University of South Carolina, Charleston, SC, 13Cohen Children's Medical Center, Lake Success, NY, 14Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 15Boston Children's Hospital, Boston, MA, 16Stanford University School of Medicine, Palo Alto, CA, 17Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 18University of Alabama at Birmingham, Birmingham, AL, 19Nationwide Children's Hospital, Columbus, OH, 20University of Mississippi Medical Center, Jackson, MS, 21Phoenix Children's Hospital, Phoenix, AZ, 22Nemours Foundation, Orlando, FL, 23Seattle Children's Hospital, Seattle, WA

Meeting: ACR Convergence 2024

Keywords: Disparities, Juvenile idiopathic arthritis, Patient reported outcomes, Pediatric rheumatology, registry

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Healthcare Disparities in Rheumatology Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: As healthcare moves towards more patient-centered care, it is increasingly important to integrate patients’ opinions into clinical assessments and decision-making. The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning health network dedicated to improving healthcare delivery and patient outcomes in juvenile idiopathic arthritis (JIA) through quality improvement methodology. PR-COIN focuses on outcome improvements by measuring disease control, relief of pain, and optimization of physical function through a ‘treat to target’ strategy. These health domains were prioritized by patients and are therefore collected as quality measures in PR-COIN. Our project stratified patient-reported outcomes including the percent of patients with JIA in the PR-COIN registry who had a low patient/parent global assessment of wellbeing score (PtGA), no or mild pain, and optimal physical function by race, ethnicity, and insurance type.

Methods: We assessed PR-COIN network-level data over time from January 2016 to May 2024 on run charts and calculated the mean performance on the patient-reported outcomes during this time frame. A low PtGA value indicates a score of ≤2. No or mild pain equates to a score of ≤3 on the arthritis-related pain intensity scale. Optimal physical function is measured as a score of 0 on the Childhood Health Assessment Questionnaire or score of 40 or higher on PROMIS Mobility or Upper Extremity Function. Race categories examined in this analysis include White, Black or African American, and Asian; other categories were excluded due to small sample size. Ethnicity is reported as Hispanic or non-Hispanic. We assessed two different types of insurance coverage: Medicaid and commercial.

Results: A lower percentage of Black or African American patients with JIA had PtGA scores ≤2 (60.3%), mild or no pain (64.7%), and optimal physical function (60%) compared to White patients (74.8%, 76.5%, 72.2%) (Figure 1). There has not been an apparent difference in outcomes over time between Hispanic and non-Hispanic patients with JIA on these same measures (Figure 2). Fewer patients with JIA on Medicaid had low PtGA scores (68.1%), low pain scores (71%), and optimal physical function (65.9%) compared to patients with commercial insurance (76.7%, 79.3%, 75%) (Figure 3).

Conclusion: We found disparities in patient-reported outcomes in our JIA cohort in the PR-COIN registry according to race and insurance type. In particular, Black or African American patients had worse PtGA scores, pain scores, and physical function compared to patients of White or Asian race, and a similar pattern was found between patients with Medicaid compared to patients with commercial insurance. PR-COIN will monitor the impact of quality improvement interventions to optimize care for patients with JIA by stratifying data by race, ethnicity, and insurance in an attempt to reduce inequities in patient outcomes and monitor for inadvertent exacerbation of these findings.

Supporting image 1

Figure 1. Patient-Reported Outcomes by Race.

Supporting image 2

Figure 2. Patient-Reported Outcomes by Ethnicity.

Supporting image 3

Figure 3. Patient-Reported Outcomes by Insurance Type.


Disclosures: J. Harris: None; N. Pan: None; C. Bingham: None; S. Vora: None; C. Yildirim-Toruner: None; K. Ferraro: None; E. Friedrichsen: None; M. Batthish: Abbvie, 6, Novartis, 2, Viatris, 12, Unrestricted Educational Grant; J. Burnham: None; D. Fair: None; S. Ganguli: None; M. Gilbert: None; B. Gottlieb: None; O. Halyabar: None; M. Hazen: None; T. Lee: None; D. Lovell: AstraZeneca, 12, Consultant, money paid to employer, not individual, Bristol-Myers Squibb(BMS), 5, 12, Contract, money paid to employer, not individual, GlaxoSmithKlein(GSK), 12, Consultant, money paid to employer, not individual, Janssen, 12, Contract, money paid to employer, not individual, Novartis, 12, Consultant, money paid to employer, not individual, Pfizer, 12, DSMB, money paid to employer, not individual, 12, Consultant, money paid to employer, not individual, Roche, 12, Contract, money paid to employer, not individual, United Bioscience Corporation, 12, Consultant, money paid to employer, not individual; M. Mannion: NIAMS K23AR081410, 5, Rheumatology Research Foundation, 5; E. Oberle: None; L. Ray: None; M. Shishov: AbbVie/Abbott, 2, Novartis, 2; M. Toth: None; E. Morgan: Pfizer, 5.

To cite this abstract in AMA style:

Harris J, Pan N, Bingham C, Vora S, Yildirim-Toruner C, Ferraro K, Friedrichsen E, Batthish M, Burnham J, Fair D, Ganguli S, Gilbert M, Gottlieb B, Halyabar O, Hazen M, Lee T, Lovell D, Mannion M, Oberle E, Ray L, Shishov M, Toth M, Morgan E. Assessment of Patient-Reported Outcomes in Juvenile Idiopathic Arthritis by Race, Ethnicity, and Insurance Type in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/assessment-of-patient-reported-outcomes-in-juvenile-idiopathic-arthritis-by-race-ethnicity-and-insurance-type-in-the-pediatric-rheumatology-care-and-outcomes-improvement-network-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-patient-reported-outcomes-in-juvenile-idiopathic-arthritis-by-race-ethnicity-and-insurance-type-in-the-pediatric-rheumatology-care-and-outcomes-improvement-network-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology